ZEGFROVY
Jul 21, 2025
Dizal’s ZEGFROVY Approval Heating Up EGFR NSCLC Drug Rivalry with J&J
Eight years after its founding, partly backed by AstraZeneca, Dizal Pharmaceuticals has secured its first FDA approval, receiving accelerated clearance for ZEGFROVY (sunvozertinib)—now the only FDA-approved oral therapy for a rare subset of non-small cell lung cancer (NSCLC). The treatment is indicated for U.S. ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
